Immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis

T. Hibi, Yasushi Iwao, T. Yajima, Nagamu Inoue, Y. Ueno, Hiromasa Takaishi, M. Watanabe, H. Ishii

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Low doses of 6-mercaptopurine (6MP) were used for the treatment of inflammatory bowel disease, and 20-30 mg/day was found to be effective for patients with ulcerative colitis who were corticosteroid-dependent or corticosteroid-resistant. Corticosteroid was tapered in 20 of 21 patients with ulcerative colitis. Of 15 patients who were refractory to conventional therapy, 11 responded to 6MP treatment. The same doses of 6MP were given to patients with Crohn's disease who were corticosteroid-dependent or who had associated fistula. Treatment with 6MP did not influence the changes in colonic or ileac lesions in Crohn's disease. However, the fistulas were closed or improved in 70% of 10 patients by 6MP treatment. The adverse effects of small doses of 6MP were minimal. These results confirm that immunosuppressive agents are effective for patients with inflammatory bowel disease. In a rat colitis model induced by immunization with trinitrobenzene (TNB), we used anti-CD4 monoclonal antibodies to prevent colonic inflammation; these antibodies were effective for this colitis model, suggesting that a novel therapy targeting CD4 intestinal lymphocytes may be feasible in the treatment of Crohn's disease.

Original languageEnglish
Pages (from-to)121-123
Number of pages3
JournalJournal of Gastroenterology
Volume30
Issue numberSUPPL. 8
Publication statusPublished - 1995

Fingerprint

6-Mercaptopurine
Immunosuppressive Agents
Ulcerative Colitis
Crohn Disease
Adrenal Cortex Hormones
Colitis
Therapeutics
Fistula
Trinitrobenzenes
Inflammatory Bowel Diseases
Immunization
Monoclonal Antibodies
Lymphocytes
Inflammation
Antibodies

Keywords

  • 6 mercaptopurine (6MP)
  • CD4
  • Crohn's disease
  • Immunosuppressive agents
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis. / Hibi, T.; Iwao, Yasushi; Yajima, T.; Inoue, Nagamu; Ueno, Y.; Takaishi, Hiromasa; Watanabe, M.; Ishii, H.

In: Journal of Gastroenterology, Vol. 30, No. SUPPL. 8, 1995, p. 121-123.

Research output: Contribution to journalArticle

Hibi, T, Iwao, Y, Yajima, T, Inoue, N, Ueno, Y, Takaishi, H, Watanabe, M & Ishii, H 1995, 'Immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis', Journal of Gastroenterology, vol. 30, no. SUPPL. 8, pp. 121-123.
Hibi, T. ; Iwao, Yasushi ; Yajima, T. ; Inoue, Nagamu ; Ueno, Y. ; Takaishi, Hiromasa ; Watanabe, M. ; Ishii, H. / Immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis. In: Journal of Gastroenterology. 1995 ; Vol. 30, No. SUPPL. 8. pp. 121-123.
@article{a900855c67d84cbe9e3e63827fa05077,
title = "Immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis",
abstract = "Low doses of 6-mercaptopurine (6MP) were used for the treatment of inflammatory bowel disease, and 20-30 mg/day was found to be effective for patients with ulcerative colitis who were corticosteroid-dependent or corticosteroid-resistant. Corticosteroid was tapered in 20 of 21 patients with ulcerative colitis. Of 15 patients who were refractory to conventional therapy, 11 responded to 6MP treatment. The same doses of 6MP were given to patients with Crohn's disease who were corticosteroid-dependent or who had associated fistula. Treatment with 6MP did not influence the changes in colonic or ileac lesions in Crohn's disease. However, the fistulas were closed or improved in 70{\%} of 10 patients by 6MP treatment. The adverse effects of small doses of 6MP were minimal. These results confirm that immunosuppressive agents are effective for patients with inflammatory bowel disease. In a rat colitis model induced by immunization with trinitrobenzene (TNB), we used anti-CD4 monoclonal antibodies to prevent colonic inflammation; these antibodies were effective for this colitis model, suggesting that a novel therapy targeting CD4 intestinal lymphocytes may be feasible in the treatment of Crohn's disease.",
keywords = "6 mercaptopurine (6MP), CD4, Crohn's disease, Immunosuppressive agents, Ulcerative colitis",
author = "T. Hibi and Yasushi Iwao and T. Yajima and Nagamu Inoue and Y. Ueno and Hiromasa Takaishi and M. Watanabe and H. Ishii",
year = "1995",
language = "English",
volume = "30",
pages = "121--123",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "SUPPL. 8",

}

TY - JOUR

T1 - Immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis

AU - Hibi, T.

AU - Iwao, Yasushi

AU - Yajima, T.

AU - Inoue, Nagamu

AU - Ueno, Y.

AU - Takaishi, Hiromasa

AU - Watanabe, M.

AU - Ishii, H.

PY - 1995

Y1 - 1995

N2 - Low doses of 6-mercaptopurine (6MP) were used for the treatment of inflammatory bowel disease, and 20-30 mg/day was found to be effective for patients with ulcerative colitis who were corticosteroid-dependent or corticosteroid-resistant. Corticosteroid was tapered in 20 of 21 patients with ulcerative colitis. Of 15 patients who were refractory to conventional therapy, 11 responded to 6MP treatment. The same doses of 6MP were given to patients with Crohn's disease who were corticosteroid-dependent or who had associated fistula. Treatment with 6MP did not influence the changes in colonic or ileac lesions in Crohn's disease. However, the fistulas were closed or improved in 70% of 10 patients by 6MP treatment. The adverse effects of small doses of 6MP were minimal. These results confirm that immunosuppressive agents are effective for patients with inflammatory bowel disease. In a rat colitis model induced by immunization with trinitrobenzene (TNB), we used anti-CD4 monoclonal antibodies to prevent colonic inflammation; these antibodies were effective for this colitis model, suggesting that a novel therapy targeting CD4 intestinal lymphocytes may be feasible in the treatment of Crohn's disease.

AB - Low doses of 6-mercaptopurine (6MP) were used for the treatment of inflammatory bowel disease, and 20-30 mg/day was found to be effective for patients with ulcerative colitis who were corticosteroid-dependent or corticosteroid-resistant. Corticosteroid was tapered in 20 of 21 patients with ulcerative colitis. Of 15 patients who were refractory to conventional therapy, 11 responded to 6MP treatment. The same doses of 6MP were given to patients with Crohn's disease who were corticosteroid-dependent or who had associated fistula. Treatment with 6MP did not influence the changes in colonic or ileac lesions in Crohn's disease. However, the fistulas were closed or improved in 70% of 10 patients by 6MP treatment. The adverse effects of small doses of 6MP were minimal. These results confirm that immunosuppressive agents are effective for patients with inflammatory bowel disease. In a rat colitis model induced by immunization with trinitrobenzene (TNB), we used anti-CD4 monoclonal antibodies to prevent colonic inflammation; these antibodies were effective for this colitis model, suggesting that a novel therapy targeting CD4 intestinal lymphocytes may be feasible in the treatment of Crohn's disease.

KW - 6 mercaptopurine (6MP)

KW - CD4

KW - Crohn's disease

KW - Immunosuppressive agents

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=0028842680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028842680&partnerID=8YFLogxK

M3 - Article

C2 - 8563872

AN - SCOPUS:0028842680

VL - 30

SP - 121

EP - 123

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - SUPPL. 8

ER -